Skip to main content
. Author manuscript; available in PMC: 2016 Sep 15.
Published in final edited form as: Clin Cancer Res. 2015 May 12;21(18):4048–4054. doi: 10.1158/1078-0432.CCR-15-0215

Table 1.

Dose modification plan

LVEF Decline
Resulting LVEF None <10% 10–15% ≥ 16%
0% < ILN Continue Continue Continue Discontinue treatment
1–5% < ILN Continue and repeat MUGA Continue and repeat MUGA Hold drug/repeat MUGA
≥ 6% Below ILN Continue and repeat MUGA Hold drug/repeat MUGA Hold drug/repeat MUGA